Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
2026-01-23 15:52:44 ET
The last time I spoke about Bristol-Myers Squibb ( BMY ) it was with respect to a Seeking Alpha article entitled " Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth ". In this article, I noted that the company was seeing robust growth as part of its "Growth Portfolio" of products to counter the losses incurred in its "Legacy Portfolio". Two sectors in particular were its hematology and cardiovascular products. I also mentioned that the company had reported its Q3 of 2025 earnings as well, showcasing growth in its "Growth Portfolio". Today, I want to go over three key items....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
NASDAQ: JANX
JANX Trading
1.39% G/L:
$13.84 Last:
423,659 Volume:
$13.65 Open:
